Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression

Abstract Background and aims Diabetes Mellitus (DM) is chronic conditions with devastating multi-systemic complication and may be associated with severe form of Coronavirus Disease 2019 (COVID-19). We conducted a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with COVID-19 pneumonia. Methods Systematic literature search was performed from several electronic databases on subjects that assess DM and outcome in COVID-19 pneumonia. The outcome of interest was composite poor outcome, including mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care, and disease progression. Results There were a total of 6452 patients from 30 studies. Meta-analysis showed that DM was associated with composite poor outcome (RR 2.38 [1.88, 3.03], p < 0.001; I2: 62%) and its subgroup which comprised of mortality (RR 2.12 [1.44, 3.11], p < 0.001; I2: 72%), severe COVID-19 (RR 2.45 [1.79, 3.35], p < 0.001; I2: 45%), ARDS (RR 4.64 [1.86, 11.58], p = 0.001; I2: 9%), and disease progression (RR 3.31 [1.08, 10.14], p = 0.04; I2: 0%). Meta-regression showed that the association with composite poor outcome was influenced by age (p = 0.003) and hypertension (p < 0.001). Subgroup analysis showed that the association was weaker in studies with median age ≥55 years-old (RR 1.92) compared to <55 years-old (RR 3.48), and in prevalence of hypertension ≥25% (RR 1.93) compared to <25% (RR 3.06). Subgroup analysis on median age <55 years-old and prevalence of hypertension <25% showed strong association (RR 3.33) Conclusion DM was associated with mortality, severe COVID-19, ARDS, and disease progression in patients with COVID-19.

[1]  Han-Qing Liu,et al.  Epidemiological Characteristics of 417 patients infected with COVID-19 and 368 discharged cases among them in Shenzhen City, China , 2020 .

[2]  Lei Liu,et al.  Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China , 2020 .

[3]  Xinghuan Wang,et al.  Clinical Characteristics And Risk Factors For Fatal Outcome in Patients With 2019-Coronavirus Infected Disease (COVID-19) in Wuhan, China , 2020 .

[4]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[5]  Lei Liu,et al.  COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China , 2020, medRxiv.

[6]  S. Mimura,et al.  The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan , 2020, medRxiv.

[7]  Wenwu Sun,et al.  Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019 , 2020, medRxiv.

[8]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Geng,et al.  Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China , 2020, medRxiv.

[10]  E. Lakatta,et al.  The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. , 2020, JAMA cardiology.

[11]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[12]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[13]  Zhichao Feng,et al.  Early Prediction of Disease Progression in 2019 Novel Coronavirus Pneumonia Patients Outside Wuhan with CT and Clinical Characteristics , 2020, medRxiv.

[14]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[15]  Chang Hu,et al.  Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, Journal of Clinical Virology.

[16]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[17]  Hongzhou Lu,et al.  Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China , 2020, medRxiv.

[18]  G. Zhen,et al.  Radiographic Findings and other Predictors in Adults with Covid-19 , 2020, medRxiv.

[19]  Ritesh Gupta,et al.  Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc) , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[20]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[21]  S. Mimura,et al.  Non-Severe vs Severe Symptomatic COVID-19: 104 Cases from the Outbreak on the Cruise Ship 'Diamond Princess' in Japan , 2020 .

[22]  Heng Fan,et al.  Diabetes is a risk factor for the progression and prognosis of COVID‐19 , 2020, Diabetes/metabolism research and reviews.

[23]  R. Buzzetti,et al.  Covid‐19 and diabetes mellitus: unveiling the interaction of two pandemics , 2020, Diabetes/metabolism research and reviews.

[24]  Wei Liu,et al.  Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease , 2020, Chinese medical journal.

[25]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[26]  World Health Organization,et al.  Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance , 2020, Pediatria i Medycyna Rodzinna.

[27]  COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China , 2020, Allergy.

[28]  P. Santisteban,et al.  Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats. , 2015, Endocrinology.

[29]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[30]  Hongzhou Lu,et al.  Clinical Characteristics of SARS-CoV-2 Infections Involving 325 Hospitalized Patients outside Wuhan , 2020 .

[31]  R. Holt,et al.  COVID‐19 and diabetes , 2020, Diabetic medicine : a journal of the British Diabetic Association.

[32]  Wen Yin,et al.  Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, medRxiv.

[33]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[34]  Lijuan Xiong,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[35]  Rui Song,et al.  Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage , 2020, medRxiv.

[36]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[37]  Chang Hu,et al.  Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, medRxiv.

[38]  L. Lei,et al.  Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing，China , 2020, medRxiv.

[39]  T. Guo,et al.  Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China , 2020, medRxiv.

[40]  Gian Paolo Rossi,et al.  Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients , 2020, eLife.

[41]  S. Geerlings,et al.  Immune dysfunction in patients with diabetes mellitus (DM). , 1999, FEMS immunology and medical microbiology.

[42]  J. Shaw,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.

[43]  Chang Hu,et al.  Clinical Features and Treatment of 221 Patients with COVID-19 in Wuhan, China , 2020 .

[44]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[45]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[46]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[47]  Xiao Chen,et al.  Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19 , 2020, Journal of medical virology.

[48]  Y. Xiong,et al.  Clinical features and treatment of COVID‐19 patients in northeast Chongqing , 2020, Journal of medical virology.

[49]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[50]  Anil Bhansali,et al.  COVID-19, diabetes mellitus and ACE2: The conundrum , 2020, Diabetes Research and Clinical Practice.

[51]  K. Nugent,et al.  The Effect of Short‐Term Hyperglycemia on the Innate Immune System , 2016, The American journal of the medical sciences.